UNSPSC 51384606: Bisfenazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H29N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OA32ZIB31, chemically known as 3-(((2,3-dimethyl-5-oxo-1-phenyl-3-pyrzolin-4-yl)amino)methyl)-4-isopropyl-2-methyl-1-phenyl-3-pyrazolin-5-one but generally known as bisfenazone, which bears US NIH Compound Identifier 189866. European Medicines Agency schedules Bisfenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05851MIG.

UNSPSC 51384606 Bisfenazone is a Commodity code nominally tied to a specific chemical compound, but recent state and local procurement activity under this code shows minimal direct relevance to that substance. The three most recent opportunities posted under the code involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative focused on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The actual work being solicited spans community health procurement, pharmacy benefit program restructuring, and pharmaceutical supply agreements — none of which map directly to bisfenazone procurement. This indicates either misclassification in the state and local sourcing systems or a code whose nominal scope has drifted from recent buying activity.

Activity under this code appears sparse and geographically scattered. Recent solicitations originate from Florida (county-level health procurement), Texas (state health and human services), and Minnesota (multistate cooperative purchasing). The Seminole County IFB closed July 26, 2023 (now expired), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS RFI posted April 3, 2026 was exploratory in nature, gathering vendor capability information for a future formal RFP on direct-to-manufacturer prescription models without a binding timeline or award value. The Minnesota MMCAP RFP, posted January 20, 2026 with a March 26, 2026 response deadline, sought generic pharmaceutical and OTC product manufacturers to supply through three authorized wholesalers, with contract term beginning July 1, 2026 and a 3 percent administrative fee structure. Given the mismatch between the code's nominal substance and the actual scope of recent opportunities, buyers should treat this code as low-signal and confirm the correct classification before pursuing activity.